Ondine Biomedical announces that its Phase 2 BENEFIT-APDT clinical trial has met the primary endpoint of bacterial load reduction after nasal photodisinfection. Results from the study showed that nasal photodisinfection eliminated or significantly decreased S. aureus in 92% of carriers (P<0.001) immediately after treatment. There were no reportable adverse events or unexpected safety issues; treatment was found to be safe and well tolerated.
Carolyn Cross, CEO of Ondine Biomedical, commented, “As expected, photodisinfection had a strong antimicrobial outcome, which we believe, from our Canadian hospital experiences, will be beneficial to pre-surgical patients. Concluding our Phase 2 trial is a key milestone that satisfies our IPO commitment and puts us firmly on the path towards completing the US FDA regulatory process.”